Revolution Medicines' pancreatic cancer drug Rasonque posts one of oncology's best launches
Rasonque's early commercial performance is being watched as a test of demand for targeted RAS inhibitors in a tumor type with few treatment options.
Read at STAT →Full coverage · 10 outlets
- STAT · lead
- BioSpaceRevMed’s Rasonque gets a subtype data asterisk, but analysts remain bullish
- BioPharma DiveRevolution pancreatic cancer drug should quickly become a blockbuster, analysts say
- Pancreatic Cancer Action NetworkFirst RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know
- The New York TimesA $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
- Technology OrgRasonque Lung Cancer Data: What the 42% Really Means
- Boston HeraldPancreatic cancer pill priced above $475,000 a year
- GizmodoThis Pill Will Change Cancer Treatment Forever
- MarketBeatRevolution Medicines Got Its Breakthrough-What Moves It Next?
- MSNRevolution Medicines wins EU committee backing for pancreatic cancer treatment